AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).  
 

News

AzurRx BioPharma, Inc. (NASDAQ:AZRX) is "One to Watch"

🕔6/15/2017 6:15:00 AM 4801

(NetworkNewsWire) With more than a century of combined experience spanning the gamut from pancreas/GI tract issues in hepato-gastroenterology and infectious disease to the development of novel non-systemic (localized) therapeutic biologics and proteomics (protein engineering), the AzurRx BioPharma, Inc. (NASDAQ:AZRX) core science team is the real strength behind the company's developing portfolio of recombinant therapies.

Read Full Article

AzurRx BioPharma, Inc. (NASDAQ:AZRX) Overcoming Current Exocrine Pancreatic Insufficiency Treatment Limitations

🕔4/1/2017 6:20:00 AM 3191

(NetworkNewsWire) Exocrine Pancreatic Insufficiency, or EPI, is a problem in a person's digestive system. Simply put, EPI is when the pancreas cannot produce enough of the enzymes that the body requires to break down and absorb nutrients. Unfortunately, this means that the body is unable to absorb the right fats and nutrients, often leading to weight loss.<br /><br />There are a number of causes for EPI, such as inflammation of the pancreas; effects from surgery on the pancreas, intestines, or stomach; or even an inherited disease such as cystic fibrosis, Shwachman-Diamond syndrome, Crohn's Disease, diabetes, or celiac disease. Symptoms do vary, but normally the patient will feel a pain or tenderness in the abdomen, problems with bowel movements, flatulence, and a feeling of being full.<br /><br />Today, there has been a rise in the number of people with EPI, and this has been largely attributed to an increase in the number of patients diagnosed with diabetes and cystic fibrosis (CF). ...

Read Full Article
###

2,179 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 4) (Last 30 Days: 14) (Since Published: 2179) 

Company Data